Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis

H. Lastuvkova, Z. Nova, M. Hroch, F. Alaei Faradonbeh, J. Schreiberova, J. Mokry, H. Faistova, A. Stefela, J. Dusek, O. Kucera, R. Hyspler, E. Dohnalkova, RL. Bayer, P. Hirsova, P. Pavek, S. Micuda

. 2023 ; 196 (2) : 200-217. [pub] 2023Nov28

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000602

Grant support
R01DK130884 NIDDK NIH HHS - United States

Carvedilol is a widely used beta-adrenoreceptor antagonist for multiple cardiovascular indications; however, it may induce cholestasis in patients, but the mechanism for this effect is unclear. Carvedilol also prevents the development of various forms of experimental liver injury, but its effect on nonalcoholic steatohepatitis (NASH) is largely unknown. In this study, we determined the effect of carvedilol (10 mg/kg/day p.o.) on bile formation and bile acid (BA) turnover in male C57BL/6 mice consuming either a chow diet or a western-type NASH-inducing diet. BAs were profiled by liquid chromatography-mass spectrometry and BA-related enzymes, transporters, and regulators were evaluated by western blot analysis and qRT-PCR. In chow diet-fed mice, carvedilol increased plasma concentrations of BAs resulting from reduced BA uptake to hepatocytes via Ntcp transporter downregulation. Inhibition of the β-adrenoreceptor-cAMP-Epac1-Ntcp pathway by carvedilol may be the post-transcriptional mechanism underlying this effect. In contrast, carvedilol did not worsen the deterioration of BA homeostasis accompanying NASH; however, it shifted the spectra of BAs toward more hydrophilic and less toxic α-muricholic and hyocholic acids. This positive effect of carvedilol was associated with a significant attenuation of liver steatosis, inflammation, and fibrosis in NASH mice. In conclusion, our results indicate that carvedilol may increase BAs in plasma by modifying their liver transport. In addition, carvedilol provided significant hepatoprotection in a NASH murine model without worsening BA accumulation. These data suggest beneficial effects of carvedilol in patients at high risk for developing NASH.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000602
003      
CZ-PrNML
005      
20240213093259.0
007      
ta
008      
240109s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/toxsci/kfad088 $2 doi
035    __
$a (PubMed)37632784
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lastuvkova, Hana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
245    10
$a Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis / $c H. Lastuvkova, Z. Nova, M. Hroch, F. Alaei Faradonbeh, J. Schreiberova, J. Mokry, H. Faistova, A. Stefela, J. Dusek, O. Kucera, R. Hyspler, E. Dohnalkova, RL. Bayer, P. Hirsova, P. Pavek, S. Micuda
520    9_
$a Carvedilol is a widely used beta-adrenoreceptor antagonist for multiple cardiovascular indications; however, it may induce cholestasis in patients, but the mechanism for this effect is unclear. Carvedilol also prevents the development of various forms of experimental liver injury, but its effect on nonalcoholic steatohepatitis (NASH) is largely unknown. In this study, we determined the effect of carvedilol (10 mg/kg/day p.o.) on bile formation and bile acid (BA) turnover in male C57BL/6 mice consuming either a chow diet or a western-type NASH-inducing diet. BAs were profiled by liquid chromatography-mass spectrometry and BA-related enzymes, transporters, and regulators were evaluated by western blot analysis and qRT-PCR. In chow diet-fed mice, carvedilol increased plasma concentrations of BAs resulting from reduced BA uptake to hepatocytes via Ntcp transporter downregulation. Inhibition of the β-adrenoreceptor-cAMP-Epac1-Ntcp pathway by carvedilol may be the post-transcriptional mechanism underlying this effect. In contrast, carvedilol did not worsen the deterioration of BA homeostasis accompanying NASH; however, it shifted the spectra of BAs toward more hydrophilic and less toxic α-muricholic and hyocholic acids. This positive effect of carvedilol was associated with a significant attenuation of liver steatosis, inflammation, and fibrosis in NASH mice. In conclusion, our results indicate that carvedilol may increase BAs in plasma by modifying their liver transport. In addition, carvedilol provided significant hepatoprotection in a NASH murine model without worsening BA accumulation. These data suggest beneficial effects of carvedilol in patients at high risk for developing NASH.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    12
$a nealkoholová steatóza jater $x metabolismus $7 D065626
650    _2
$a žlučové kyseliny a soli $x metabolismus $7 D001647
650    _2
$a karvedilol $x farmakologie $x metabolismus $7 D000077261
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a játra $7 D008099
650    _2
$a membránové transportní proteiny $x metabolismus $7 D026901
650    _2
$a homeostáza $7 D006706
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nova, Zuzana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Hroch, Milos $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Alaei Faradonbeh, Fatemeh $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Schreiberova, Jolana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Mokry, Jaroslav $u Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Faistova, Hana $u Department of Pathology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Stefela, Alzbeta $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Dusek, Jan $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Kucera, Otto $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000252515343 $7 xx0041536
700    1_
$a Hyspler, Radomír $u Institute of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Dohnalkova, Ester $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Bayer, Rachel L $u Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Hirsova, Petra $u Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA $1 https://orcid.org/0000000304940924 $7 xx0104768
700    1_
$a Pavek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000187694196 $7 xx0093070
700    1_
$a Micuda, Stanislav $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
773    0_
$w MED00007104 $t Toxicological sciences $x 1096-0929 $g Roč. 196, č. 2 (2023), s. 200-217
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37632784 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093256 $b ABA008
999    __
$a ok $b bmc $g 2049326 $s 1210296
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 196 $c 2 $d 200-217 $e 2023Nov28 $i 1096-0929 $m Toxicological sciences $n Toxicol Sci $x MED00007104
GRA    __
$a R01DK130884 $p NIDDK NIH HHS $2 United States
LZP    __
$a Pubmed-20240109
Back

Find record

Citation metrics

Archiving options